Update: Bayer to pay up to €10 billion to settle bulk of Roundup weedkiller cancer lawsuits

The ruling, which permanently bars California from requiring a cancer warning on glyphosate-based products, is separate from wider litigation over whether Roundup causes a type of blood cancer.
Update: Bayer to pay up to €10 billion to settle bulk of Roundup weedkiller cancer lawsuits
California’s Office of Environmental Health Hazard Assessment had listed glyphosate in July 2017 as a chemical known to the state to cause cancer, but Bayer’s Monsanto unit (which owns the product) aggressively fought California’s move.
California’s Office of Environmental Health Hazard Assessment had listed glyphosate in July 2017 as a chemical known to the state to cause cancer, but Bayer’s Monsanto unit (which owns the product) aggressively fought California’s move.

Bayer, after more than a year of talks, agreed to pay as much as €9.8 billion to settle thousands of U.S. lawsuits claiming that its widely-used weed killer Roundup caused cancer, resolving litigation that has pummeled the company’s share price.

The German drugs and pesticides maker has come to terms with about 75% of the 125,000 filed and unfiled claims overall, it said in a statement on Wednesday of the deal to end legal disputes it inherited with its $63 billion takeover of Monsanto in 2018.

The settled cases over Roundup and other glyphosate-based weedkillers account for about 95% of those currently set for trial, it added.

“The Roundup settlement is the right action at the right time for Bayer to bring a long period of uncertainty to an end,” Bayer Chief Executive Werner Baumann said.

The company said it will make a payment of $8.8 billion to $9.6 billion to resolve the current Roundup litigation - including an allowance expected to cover unresolved claims - and $1.25 billion to support a separate class agreement to address potential future litigation.

“Bayer is not getting complete relief, but trying to do as much as it can to calm uncertainty,” said Adam Zimmerman, a law professor at Loyola Law School who has followed the litigation. He called the deal creative, adding, “I can see how it’s attractive for Bayer.”

- Reuters

The deal dwarfs previous out-of-court product liability settlements, such as Merck & Co’s $5 billion deal to end litigation over its withdrawn painkiller Vioxx, and Bayer deals worth $2 billion to settle claims of harm caused by its Yasmin and Yaz birth control pills.

Monsanto began selling Roundup in 1974, and while the formulation is no longer patent-protected, Roundup remains widely available.

Bayer shares are down 29% since it close the Monsanto deal in June 2018. At one point last year as juries ruled against the company, Bayer’s market value had fallen below what it paid for Monsanto.

Bayer will continue selling Roundup and will not add a cancer warning label to the product, a company spokesman said.

More in this section

Farming
Newsletter

Keep up-to-date with all the latest developments in Farming with our weekly newsletter

Sign up
Revoiced
Newsletter

Our Covid-free newsletter brings together some of the best bits from irishexaminer.com, as chosen by our editor, direct to your inbox every Monday.

Sign up